Andexanet alfael esperado antídoto de los anticoagulantes directos inhibidores del factor Xa
ISSN: 2171-9020
Année de publication: 2019
Titre de la publication: Candidemia, ¿es necesaria la valoración rutinaria del fondo de ojo?
Volumen: 2
Número: 44
Type: Article
D'autres publications dans: MPG Journal
Résumé
Acute major bleeding episodes associated with factor Xa inhibitors (rivaroxaban, apixaban, edoxaban and enoxaparin) may be difficult to treat due to the lack of a specific reversal agent. Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors that markedly reduced anti–factor Xa activity with good hemostatic efficacy.
Références bibliographiques
- Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
- Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131- 41.
- Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol 2016; 9: 11522.
- Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-51.
- Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413-24.